Mayne Pharma Group (MAYNF)
OTHER OTC:MAYNF
Want to see MAYNF full AI Analyst Report?
MAYNF Stock Chart & Stats
$3.82
-$0.09(-2.96%)
At close: 4:00 PM EST
$3.82
-$0.09(-2.96%)
Day’s Range― - ―
52-Week Range$1.44 - $4.59
Previous CloseN/A
Volume375.00
Average Volume (3M)2.61K
Market Cap
$146.02M
Enterprise Value$190.95M
Total Cash (Recent Filing)$67.35M
Total Debt (Recent Filing)$44.62M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding81,245,830
10 Day Avg. Volume15
30 Day Avg. Volume2,610
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.11
Price to Sales (P/S)1.01
P/FCF Ratio79.25
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue0.47
Enterprise Value/Gross Profit0.86
Enterprise Value/Ebitda8.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross MarginA ~4 percentage-point gross margin uplift reflects durable mix improvement and tighter margin control, which supports higher-quality earnings even without top-line growth. Sustained margin expansion reduces sensitivity to volume swings and enhances long-term cash generation potential.
Dermatology Margin TurnaroundWide margin expansion and strong direct contribution in Dermatology indicates successful shifts toward higher‑value branded products. This structural shift to branded revenue can produce steadier margins, better pricing power, and a more defensible revenue stream versus commoditised generics.
Positive Cash Position & Operating Cash FlowPositive adjusted operating cash flow and a healthy cash balance provide liquidity to fund selective investments, margin programs and potential buybacks or tuck‑ins. A solid cash buffer reduces refinancing risk and gives management optionality for strategic execution over the medium term.
Bears Say
Weak Overall ProfitabilitySustained net losses and negative operating margins indicate the company has not yet converted improved gross margins into consistent profitability. Continued operating losses can erode equity, constrain reinvestment capacity, and limit strategic flexibility if not reversed within several quarters.
Poor Cash ConversionVery weak free cash flow trends and low conversion of reported earnings into cash highlight structural cash generation issues. Poor cash conversion reduces the firm's ability to self‑fund growth, increases dependence on external financing, and raises vulnerability to cost or revenue shocks.
Material Legal & Transaction CostsSignificant and ongoing litigation/transaction costs create uncertain cash outflows and potential contingent liabilities. Persistent legal expense can compress margins, divert management attention, and delay value extraction from strategic shifts, weakening medium‑term earnings visibility.
Mayne Pharma Group News
MAYNF FAQ
What was Mayne Pharma Group’s price range in the past 12 months?
Mayne Pharma Group lowest stock price was $1.44 and its highest was $4.59 in the past 12 months.
What is Mayne Pharma Group’s market cap?
Mayne Pharma Group’s market cap is $146.02M.
When is Mayne Pharma Group’s upcoming earnings report date?
Mayne Pharma Group’s upcoming earnings report date is Aug 20, 2026 which is in 119 days.
How were Mayne Pharma Group’s earnings last quarter?
Mayne Pharma Group released its earnings results on Feb 22, 2026. The company reported -$0.103 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.103.
Is Mayne Pharma Group overvalued?
According to Wall Street analysts Mayne Pharma Group’s price is currently Overvalued.
Does Mayne Pharma Group pay dividends?
Mayne Pharma Group pays a Notavailable dividend of $0.378 which represents an annual dividend yield of N/A. See more information on Mayne Pharma Group dividends here
What is Mayne Pharma Group’s EPS estimate?
Mayne Pharma Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mayne Pharma Group have?
Mayne Pharma Group has 81,245,830 shares outstanding.
What happened to Mayne Pharma Group’s price movement after its last earnings report?
Mayne Pharma Group reported an EPS of -$0.103 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.424%.
Which hedge fund is a major shareholder of Mayne Pharma Group?
Currently, no hedge funds are holding shares in MAYNF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mayne Pharma Group Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.78%
12-Months-Change
Fundamentals
Return on Equity
-23.02%
Trailing 12-Months
Asset Growth
-10.41%
Trailing 12-Months
Company Description
Mayne Pharma Group
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
MAYNF Company Deck
MAYNF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a generally constructive picture: the underlying business remained cash generative with improved gross margins, higher total direct contribution, strong Dermatology profitability and clear momentum across multiple Women's Health products. These positives are tempered by an 8% decline in underlying EBITDA, significant one‑off noncash earn‑out and litigation/transaction charges, elevated near‑term legal and earn‑out cash outflows, ANNOVERA returns issues and an investment phase in International that compressed contribution. Management framed many negatives as discrete or investment‑led and emphasized strategic repositioning, operational improvements and capital allocation optionality.View all MAYNF earnings summariesTechnical Analysis
Starpharma Holdings Limited
―
Vita Life Sciences Limited
―
Medical Developments International Limited
―
Botanix Pharmaceuticals Limited
―
Recce Pharmaceuticals Ltd.
―
Ownership Overview
0.34% Insiders
3.24% Mutual Funds
<0.01% Other Institutional Investors
94.28% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---